MannKind Wins FDA Approval for Afrezza Inhaled Insulin in Children Ages 6 and Older
May 31, 2026
MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.